Literature DB >> 29307199

Pathologic classification of "pancreatic cancers": current concepts and challenges.

Mohamed E Mostafa1, Ipek Erbarut-Seven2, Burcin Pehlivanoglu1, Volkan Adsay3.   

Abstract

As the most common and most important cancer of the pancreas, with rapid mortality and now also as the third leading cause of cancer-related deaths in the United States, pancreatic ductal adenocarcinoma (PDAC) has become synonymous with "pancreas cancer". PDAC is also the prototype of the "pancreatobiliary-type" adenocarcinomas, along the biliary tract, ampullary and gallbladder cancers with the similar morphology and behavior. Recent molecular profiling studies have identified distinct subsets of PDAC, potentially with different behaviors and targetability. Moreover, while PDAC is by far the most common cancer of the pancreas, there are various other types that occur in this organ and are erroneously classified together with PDAC. Many of these have different molecular and biologic characteristics that warrant their management separately although they are also technically "pancreatic cancers". While some are closely related to PDAC and have as aggressive behavior (such as adenosquamous carcinomas which are recently recognized under "basal" like category in profiling studies, which are actually even worse prognostically than PDACs), in the meantime, others such as colloid carcinoma has a much better behavior than PDAC, and as a carcinoma with intestinal lineage (MUC2/CDX2) colloid carcinoma may require an entirely different treatment approach as well. Similarly, medullary carcinomas also appear to have different biology. Additionally, non-ductal cancers such as acinar, neuroendocrine, solid-pseudopapillary neoplasms and pancreatoblastoma have their respective clinicopathologic and molecular associations and warrant careful elimination in the management and study protocols. Another very problematic aspect in the classification of "pancreas cancer" is its delineation from the cancers of neighboring organs, in particular, ampullary/duodenal and common bile duct (CBD) cancers, for which recently more refined criteria have been provided. Additionally, the possibility of metastasis from another site and lymphomas also need to be considered. In summary, there is a whole host of cancers that occur in the pancreas that ought to be considered carefully before a case is classified as an ordinary "pancreas cancer" (PDAC).

Entities:  

Keywords:  Pancreas; carcinoma differential; ductal adenocarcinoma

Mesh:

Year:  2017        PMID: 29307199     DOI: 10.21037/cco.2017.12.01

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  13 in total

Review 1.  Pathology and Molecular Characteristics of Pancreatic Cancer.

Authors:  Joseph F Kearney; Volkan Adsay; Jen Jen Yeh
Journal:  Surg Oncol Clin N Am       Date:  2021-07-22       Impact factor: 2.402

2.  High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma.

Authors:  Ke Li; Jiali Yang; Jiafei Chen; Yanshu Shi; Zhuoli Zhang; Wei Chen
Journal:  Oncol Lett       Date:  2019-12-11       Impact factor: 2.967

3.  MicroRNA-221-3p is related to survival and promotes tumour progression in pancreatic cancer: a comprehensive study on functions and clinicopathological value.

Authors:  Xuejiao Wu; Jia Huang; Zilin Yang; Ying Zhu; Yongping Zhang; Jiancheng Wang; Weiyan Yao
Journal:  Cancer Cell Int       Date:  2020-09-10       Impact factor: 5.722

4.  PDX1, a key factor in pancreatic embryogenesis, can exhibit antimetastatic activity in pancreatic ductal adenocarcinoma.

Authors:  Liya G Kondratyeva; Dina R Safina; Igor P Chernov; Eugene P Kopantzev; Sergey V Kostrov; Eugene D Sverdlov
Journal:  Cancer Manag Res       Date:  2019-07-26       Impact factor: 3.989

5.  Nomograms for predicting overall survival and cancer-specific survival in young patients with pancreatic cancer in the US based on the SEER database.

Authors:  Min Shi; Biao Zhou; Shu-Ping Yang
Journal:  PeerJ       Date:  2020-04-14       Impact factor: 2.984

6.  Pancreatic medullary carcinoma developed on a pancreatic intraductal papillary mucinous neoplasm with loss of MSH2 and MSH6 expression: a case report.

Authors:  Camille Verocq; Marie-Lucie Racu; Dominique Bafort; Gloria Butorano; Luis Perez-Casanova Garcia; Julie Navez; Marc Witterwulghe; Kieran Sheahan; Niall Swan; Jean Closset; Jean-Luc Van Laethem; Calliope Maris; Nicky D'Haene
Journal:  Diagn Pathol       Date:  2021-12-13       Impact factor: 2.644

7.  Pancreatic Colloid Carcinoma Presenting with Acute Pancreatitis.

Authors:  Masakuni Fujii; Yuki Okamoto; Shin-Ichi Fujioka; Junji Shiode
Journal:  Intern Med       Date:  2021-10-19       Impact factor: 1.282

Review 8.  Benign vs malignant pancreatic lesions: Molecular insights to an ongoing debate.

Authors:  Mahmoud Aldyab; Tony El Jabbour; Megan Parilla; Hwajeong Lee
Journal:  World J Gastrointest Surg       Date:  2021-05-27

9.  Diffuse Pancreatic Carcinoma with Hepatic Metastases.

Authors:  Hoang Quan Nguyen; Ngoc Trinh Thi Pham; Van Trung Hoang; Hoang Anh Thi Van; Chinh Huynh; Duc Thanh Hoang
Journal:  Case Rep Oncol Med       Date:  2020-10-30

Review 10.  A Review on the Efficacy and Safety of Nab-Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer.

Authors:  Christian Chapa-González; Karina López; Kimberly Michelle Lomelí; Jorge Alberto Roacho-Pérez; Jazmín Cristina Stevens
Journal:  Life (Basel)       Date:  2022-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.